CBB ... cite the P3 data from a large international double blinded trial that the sales reps can use to market the benefit Vascepa may have in reducing Covid hospitalization rates .
Right ... you don’t have any
Well Ok ... cite the P2 data from at least 1,000 US Covid patients on Vascepa
Oh wait .... no P2 data
Ok ... well march into the MD offices with a print out on the reduction in inflammatory markers done in a small trial in Canada .... and see how you get treated
The results re Covid patients on Vascepa so far are ENCOURAGING . That’s it
Oh by the way .... no BP will offer a price you or the BOD would accept right now ... but you know this and the reasons why ... correct ?
Market Data 
Markets 
AI
